DSG1 and pemphigus: Monoclonal antibodies targeting CD19+ (a B-cell surface molecule which is also expressed on antibody producing plasma cells) such as inebilizumab, would be an effective strategy in pemphigus, since persistence of long-lived plasmablasts producing anti-Dsg IgG autoantibodies is presumably amongst the mechanisms of disease resistance to RTX treatment (125).